Cibc World Market Inc. Has $30.78 Million Stock Position in Novo Nordisk A/S $NVO

Cibc World Market Inc. lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 15.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 554,647 shares of the company’s stock after selling 99,416 shares during the period. Cibc World Market Inc.’s holdings in Novo Nordisk A/S were worth $30,777,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Lockheed Martin Investment Management Co. increased its position in Novo Nordisk A/S by 179.4% during the 2nd quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock valued at $2,999,000 after purchasing an additional 27,900 shares during the period. Martin Capital Partners LLC boosted its stake in shares of Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after purchasing an additional 41,129 shares during the last quarter. Markel Group Inc. increased its position in shares of Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after buying an additional 110,061 shares during the period. Cantor Fitzgerald Investment Advisors L.P. bought a new position in Novo Nordisk A/S during the third quarter worth $1,294,000. Finally, WCM Investment Management LLC raised its stake in Novo Nordisk A/S by 3.7% during the third quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company’s stock worth $151,636,000 after buying an additional 97,477 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $48.77 on Thursday. The business’s fifty day moving average is $53.69 and its 200 day moving average is $53.39. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a market cap of $217.78 billion, a P/E ratio of 14.06 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s payout ratio is 52.74%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Competitor disruption: Hims & Hers pulled compounded semaglutide after regulatory and patent pressure, reducing a lower‑priced competitor and supporting Novo’s pricing and market share. Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide
• Positive Sentiment: Patent enforcement: Novo opened a U.S. patent lawsuit against Hims over Wegovy copies — a move that could deter copycat suppliers and protect revenue. Novo Nordisk opens new front with patent suit over Hims’ Wegovy copies
• Positive Sentiment: Product expansion: Novo plans to launch Wegovy in vials, expanding formulation options and potentially improving uptake and manufacturing flexibility for the obesity pill. Novo Nordisk plans to launch Wegovy vials
• Positive Sentiment: Demand signal: A study shows many Wegovy pill users were new to GLP‑1 treatments, implying the drug is expanding the market rather than just displacing existing patients. Many users of Novo Nordisk Wegovy pill new to GLP-1s – study
• Neutral Sentiment: Medicare opportunity: CEO Mike Doustdar highlighted a potential 15 million‑patient opportunity if Medicare covers obesity treatments — a meaningful long‑term revenue opportunity but one that won’t open overnight. Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
• Neutral Sentiment: Insider trading disclosures: The company filed routine disclosures showing trades by board members and executives; such filings are standard but watched by investors for signal. Trading in Novo Nordisk shares by board members, executives and associated persons
• Neutral Sentiment: Company narrative: Coverage notes 2026 as a “show me” year—management is focused on defending share amid a dramatic pill launch and intensifying competition; this frames both upside and execution risk. Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
• Negative Sentiment: Regulatory pressure: The FDA flagged a TV ad for the Wegovy pill as misleading and broader FDA warnings plus lawsuits are testing Novo’s valuation and investor confidence. Novo’s TV ad for Wegovy pill had misleading claims, FDA says
• Negative Sentiment: Analyst pressure: Deutsche Bank cut its price target and Zacks downgraded Novo to “strong sell,” reflecting concern after softer guidance and revenue headwinds — analyst moves can amplify selling pressure. Novo Nordisk target cut by Deutsche Bank despite long-term optimism Zacks.com downgrade
• Negative Sentiment: Guidance and growth concerns: Articles highlight weak 2026 outlook and slowing sales growth for Ozempic/Wegovy, which is the primary fundamental reason investors are trimming exposure. Is Novo Nordisk’s Turnaround Story at Risk After Weak 2026 Outlook?

Analyst Ratings Changes

A number of brokerages have weighed in on NVO. CICC Research started coverage on Novo Nordisk A/S in a report on Friday, January 9th. They set an “outperform” rating and a $73.50 price target for the company. Jefferies Financial Group began coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating on the stock. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, February 5th. HSBC restated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, TD Cowen reiterated a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.